Source comparison
Stop Taking Melanotan-1: Discontinuation Method Comparison
Abrupt cessation 28–42 days Immediate (within 72 hours) 10–14 days Low. Stop injections, resume sun protection immediately Pharmacologically sound. No withdrawal risk. Fastest return to baseline receptor sensitivity. Gradual taper (25% reduction every 3–4 days
This comparison does not assign a generated winner or score.
- Abrupt cessation
- 28–42 days
- Immediate (within 72 hours)
- 10–14 days
- Low. Stop injections, resume sun protection immediately
- Pharmacologically sound. No withdrawal risk. Fastest return to baseline receptor sensitivity.
- Gradual taper (25% reduction every 3–4 days)
- 35–50 days
- Gradual over 10–14 days
- 14–21 days (delayed due to continued agonist exposure)
- Moderate. Requires dose calculation and injection schedule adjustment
- No mechanistic advantage over abrupt cessation. Delays receptor recovery. May reduce subjective 'crash' perception.
- Microdosing bridge (0.1–0.25mg every 3–5 days for 2–3 weeks)
- 42–60 days
- Partial retention for 2–3 weeks, then rapid loss
- 21–28 days
- High. Requires precise reconstitution, extended injection timeline, unclear endpoint
- Extends melanocyte stimulation without maintaining therapeutic pigmentation. Not supported by clinical evidence. Delays full discontinuation.
- Cold turkey with aggressive sun avoidance
- Immediate, but mitigated by zero UV exposure
- Moderate. Requires strict behavioral change, indoor/evening activity planning
- Safest approach for individuals with high baseline photosensitivity or history of melanoma. Eliminates rebound burn risk entirely.
- The comparison makes clear: abrupt cessation combined with immediate return to baseline photoprotection is the most efficient, evidence-aligned discontinuation method. Extended tapering or microdosing protocols delay receptor recovery without offering measurable benefit.